ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0704

Anti-SSa/SSb and Ro52 and Interstitial Lung Disease in Idiopathic Inflammatory Myopathies
Abstract Number: 0965

Anti-TNF Usage in Patients with HIV Infection 2003-2021: Long Term Safety and Followup
Abstract Number: 0696

Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer – A Longitudinal Study
Abstract Number: 1916

Antibodies to Malondialdehyde-Acetaldehyde (MAA) Modified Proteins Predict Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1540

Antibody Response After SARS-CoV-2 Infection in Patients with Rheumatic Diseases: A Multicenter, Nationwide Study
Abstract Number: 0876

Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Abstract Number: 0967

Antigen-specific and Bystander Autoreactive T Cell Control in Peripheral Blood of ACPA+ Rheumatoid Arthritis Patients Administered Antigen-specific Tolerising Immunotherapy
Abstract Number: 0137

Antiviral Use and Healthcare Resource Utilization Among Patients with Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016–2019
Abstract Number: 1703

AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis
Abstract Number: 0326

Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations
Abstract Number: 0652

Application of a GCA Probability Score to Patients Referred to a GCA Fast Track Clinic
Abstract Number: 0851

Application of a Modified Recursive Feature Elimination Machine Learning Algorithm to Select Predictors of Mortality in Those with and Without Osteoarthritis
Abstract Number: 0746

Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible?
Abstract Number: 1794

Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Psoriatic Arthritis Patients
Abstract Number: 0794

Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Rheumatoid Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].